/
The methods that we currently recommend and any methods we recommend in the future may never gain broad market acceptance. Demonstrated HRT health risks or side effects, as well as negative publicity relating to the same, could negatively impact the perception of patient benefit and generate resistance and opposition from practitioners, which could limit adoption of the Biote Method and have a …
18.50% operating margin is respectable but not wide. ROIC at 26.90%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 2.5% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 22% versus the prior year, cash generation momentum has weakened.
Profitability & Returns
Revenue (TTM)
$188M
▼ -2.5% YoY
Net Income (TTM)
$13M
▲ +756.7% YoY
Op. Margin
15.43%
ROIC
22.71%
Cash Flow & Balance Sheet
FCF (TTM)
$29M
▼ -22.2% YoY
Op. Cash Flow (TTM)
$33M
▼ -22.2% YoY
Net Debt
$98M
Cash & Equiv.
$5M
3Y CAGR: +5.2%
Continue Research